Skip to main content
OpenTrials
Completed

NCT Number: NCT01276483

Treatment Response Evaluation in Gastrointestinal Stromal Tumor (GIST) Patients

The purpose of this study is to compare sensitivity, specificity and accuracy of PET, DW MRI and CT separately and combined for the evaluation of treatment response and progression-free survival in patients with GIST.

Completed

Looking for future studies?

Notify Me

Key information

Sex eligibility

All sexes

Study type

Observational

Primary location

Oslo University Hosptal

Oslo, 0424, Norway

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Metastatic GIST patients suitable for TKI treatment
  • GIST patients pursuing preoperative neoadjuvant TKI treatment

Exclusion criteria

  • Patients with contraindications to MRI and/or TKI treatment. For patients with renal failure, CT without intravenous contrast will be performed according to clinical practice.
  • Patients who do not sign the consent paper for any reason or do not accept the study premises or patients who wish to withdraw for any reason during the study

Treatment and study plan

Primary outcomes

  1. Radiologic-pathologic correlation

    Time frame: 2 years

Sponsors and collaborators

Lead sponsor

Oslo University Hospital

Other

Registry information

Official study title

Treatment Response Evaluation in Patients With Gastrointestinal Stromal Tumor Using PET/CT and DW MRI

Important dates

Study start
2011
Primary completion
2017
Study completion
2017
First posted
Jan 13, 2011
Registry last updated
Jun 22, 2017

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.